Abstract
Background: Cutaneous wound healing represents a morphogenetic response to injury, and it designed to restore anatomic and physiological function. Human bone marrow mesenchymal stem cells-derived exosomes (hBM-MSCs-Ex) is a promising source for cell-free therapy and skin regeneration. Methods: In this study, we investigated the therapeutic effects and underlying mechanism of hBM-MSCs-Ex on cutaneous wound healing in rats. We assessment of the role of hBM-MSCs-Ex in the two type of skin cell: human keratinocytes (HaCaT) and human dermal fibroblasts (HDFs). proliferation in vitro . Furthermore, we used a full-thickness skin wounds to evaluate the effects of hBM-MSCs-Ex on cutaneous wound healing in vivo. Results: Our results demonstrated that hBM-MSCs-Ex promote both two type of skin cell growth effectively and accelerate the cutaneous wound healing ( p <0.01). Then, we found that hBM-MSCs-Ex significantly down-regulated TGF-β1, Smad2, Smad3, and Smad4 expression, while up-regulated TGF-β3 and Smad7 expression ( p <0.05). Conclusions: In conclusion, our findings indicated that hBM-MSCs-Ex effectively promote the cutaneous wound healing through inhibiting the TGF-β/Smad signal pathway, providing a new sight for the therapeutic strategy of hBM-MSCs-Ex for the treatment of cutaneous wounds.
Evaluation of persistence and distribution of intra-dermally administered PKH26 labelled goat bone marrow derived mesenchymal stem cells in cutaneous wound healing model
